Abstract Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) remains the cornerstone in the primary and secondary prevention of cardiovascular disease. However, lack of efficacy and adverse effects mean that a substantial proportion of patients fail to achieve acceptable LDL-C levels with currently available lipid-lowering drugs. Over the last decade, inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic strategy to reduce residual cardiovascular disease risk. Binding of PCSK9 to the LDL receptor targets the receptor for lysosomal degradation. The recognition that inhibition of PCSK9 increases LDL receptor activity has led to the development of a number of approaches to directly target PCSK9. Numerous monoclonal antibodies against PCSK9 are currently being evaluated in phase 3 trials, involving various patient categories on different background lipid-lowering therapies. Current evidence shows reductions in LDL-C levels of up to 70 �ay be achieved with PCSK9 inhibition, independent of background statin therapy. This review examines the most recent evidence and future prospects for the use of PCSK9 inhibitors in the prevention of cardiovascular disease.
adverse effects     0.9999995016307927^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Adverse_effect        

PCSK9                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/PCSK9                 

PCSK9                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/PCSK9                 

LDL-C                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Low-density_lipoprotein

statin                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Statin                

cardiovascular disease        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Cardiovascular_disease

subtilisin                    1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Subtilisin            

cardiovascular disease        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Cardiovascular_disease

secondary prevention          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Preventive_healthcare 

independent                   0.9850231257813323^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Independence_(probability_theory)

receptor                      0.9999999999996589^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Receptor_(biochemistry)

LDL-C                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Low-density_lipoprotein

PCSK9                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/PCSK9                 

ay                            0.9997223780287194^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Ay                    

lysosomal                     1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Lysosome              

cardiovascular disease        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Cardiovascular_disease

phase 3                       0.9999958502220053^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Phases_of_clinical_research

type 9                        0.9999999847605069^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Ford_Type_9_transmission

low-density lipoprotein       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Low-density_lipoprotein

lipid-lowering drugs          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hypolipidemic_agent   

cornerstone                   0.9999998544469796^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cornerstone           

PCSK9                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/PCSK9                 

cholesterol                   0.9999762219013844^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Cholesterol           

efficacy                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Efficacy              

plasma                        0.9999999997176019^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Blood_plasma          

PCSK9                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/PCSK9                 

PCSK9                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/PCSK9                 

LDL-C                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Low-density_lipoprotein

LDL receptor                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/LDL_receptor          

proprotein convertase         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Proprotein_convertase 

PCSK9                         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/PCSK9                 

LDL receptor                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/LDL_receptor          

monoclonal antibodies         1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Monoclonal_antibodies 

inhibitors                    0.9999999999994316^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Enzyme_inhibitor      

